Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
Antibody–drug conjugates (ADCs) are specifically designed with the objective of delivering antineoplastic agents in the most precise and selectively targeted way, increasing the antitumoral efficacy while minimizing toxicity to normal tissues.